Trial Profile

A phase I trial of oral ETX 1153c in healthy volunteers.

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ETX 1153 (Primary)
Indications Clostridium difficile infections
Focus Adverse reactions

Most Recent Events

01 Oct 2025 According to Tangram Therapeutics media release, e-therapeutics has changed its name to Tangram Therapeutics.
09 Dec 2013 Status changed from planning to discontinued (e-Therapeutics is no longer planning to advance ETC 1153 into clinical development for C. difficile)
22 Oct 2012 Planned initiation date changed to 1 Jun 2013, according to an e-Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com